Navigation Links
SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
Date:5/17/2011

NEW YORK, May 17, 2011 /PRNewswire/ -- SyntheZyme, a sustainable chemical company founded by Richard Gross, the Herman F. Mark chair and professor of chemical and biological sciences at Polytechnic Institute of New York University (NYU-Poly), has received a $475,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation.  These competitive awards provide federal support for small, highly innovative technology businesses.

(Logo:  http://photos.prnewswire.com/prnh/20091027/NY99197LOGO)

This is the second SBIR grant for SyntheZyme. The Phase I grant, awarded in January 2010, provided funding to demonstrate the efficacy of one of SyntheZyme's core innovations — a biopesticide developed from a modified yeast strain that can protect grain and produce crops without the use of harmful chemical agents.

Due to tightened regulations and heightened concerns about the health hazards of synthetic chemical pesticides, Gross says that a safe alternative is increasingly critical. "This continued support from the National Science Foundation will help us take the final steps toward our goal — offering a safe and superior biopesticide that poses no threat to the farmers who handle the materials or to the consumers who buy their produce," Gross said.

In testing, the SyntheZyme product proved highly effective against the three major plant pathogen fungal groups that attack commercially important crops including potatoes, tomatoes, wheat, corn and rice.

The Phase II grant will allow SyntheZyme to complete additional research necessary to commercialize the biopesticide. Plans include optimizing the processes for yeast fermentation and product production, conducting field trials and performing additional toxicity and biodegradation testing.

SyntheZyme has also made significant progress in developing a highly durable, recyclable bioplastic made from yeast and fatty acids from plant oils. This unique material may be a suitable substitute for polyethylene used in disposable gloves, food packaging films and films for ice, trash and produce bags.

SyntheZyme is jointly owned by Dr. Gross and NYU-Poly. The company is also part of the New York City Accelerator for a Clean and Renewable Economy (NYC-ACRE), NYU-Poly's small-business incubator fostering clean technology and renewable energy companies in New York City.

About Polytechnic Institute of New York University

Polytechnic Institute of New York University (formerly Polytechnic University), an affiliate of New York University, is a comprehensive school of engineering, applied sciences, technology and research, and is rooted in a 157-year tradition of invention, innovation and entrepreneurship: i-squared-e. The institution, founded in 1854, is the nation's second-oldest private engineering school. In addition to its main campus in New York City at MetroTech Center in downtown Brooklyn, it also offers programs at sites throughout the region and around the globe. Globally, NYU-Poly has programs in Israel, China and is an integral part of NYU's campus in Abu Dhabi. For more information, visit www.poly.edu.

About SyntheZyme

SyntheZyme is a privately-held sustainable chemical company commercializing the technology developed in the laboratories of Professor Richard A. Gross at the Polytechnic Institute of NYU. Dr. Gross is the Herman F. Mark Professor of Polymer Science and head of the Center for Biocatalysis and Bio-processing of Macromolecules at NYU-Poly. Located in Brooklyn, N.Y., SyntheZyme uses the understanding of biocatalysis to replace petrochemical based industrial chemicals with biobased and biodegradable alternatives. Focusing on chemicals for plastics, pesticides, cosmetics and personal care product ingredients, Nature's chemistry shows the way and provides the tools that are used by SyntheZyme. For more information, visit www.SyntheZyme.com.

About New York City Accelerator for a Clean and Renewable Economy

The New York City Accelerator for a Clean and Renewable Economy (NYC ACRE) is a cleantech/renewable energy initiative of NYU-Poly, seeded by a four year, $1.5M grant from the New York State Energy and Research Development Authority (NYSERDA) aimed at growing an ecosystem of entrepreneurs, international companies, and innovative local businesses that provide solutions to climate and energy issues while growing the cleantech/renewable energy sector and creating jobs in NYC. For more information, visit www.nycacre.com.


'/>"/>
SOURCE Polytechnic Institute of New York University
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medivir AB (Nasdaq ... a new Board of Directors that will be submitted ... Committee comprises representatives of the company,s three largest shareholders ... who have accepted a seat on the Nomination Committee, ... the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... 2016" report to their offering. ... The latest research Autism Spectrum Disorder Drugs ... benchmarks in the global Autism Spectrum Disorder market. The research ... the key drugs marketed for Autism Spectrum Disorder and their clinical ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... The Smart Machine Age is here, and it’s disrupting everything. ... of all jobs in the United States may be taken over by technology in ... aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will belong ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users ... X . Users have total control over position, rotation, distortion, edge softness, edge blur, ... Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Department of Justice jointly issued a letter to withdraw previous guidance ... with their gender identity. The guidance issued in May 2016 by the Obama ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):